MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You

Conclusion

I think that both MannKind Corporation (NASDAQ:MNKD) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) have a legitimate chance of eventually producing FDA approved products. Both companies have already been through the FDA process in the past, but look more prepared for upcoming meetings.

I would like to see MannKind’s Affrezza be successful in the market – but, unfortunately, I think the competition is too stiff and that MannKind Corporation (NASDAQ:MNKD) does not have the financial flexibility to market its product. Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Contrave looks to have the strengths of both Belviq and Qsymia, without the weaknesses. Thus, I believe it could be the blockbuster that we’ve waited for in the weight loss industry.

Sherrie Stone has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article 2 Biotech Approval Outcomes That Might Affect You originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.